Perindopril

Perindopril is a pivotal ACE inhibitor API and reference standard in the cardiovascular pharmaceutical industry, distinguished by its long-acting profile and proven efficacy across multiple cardiovascular indications. As a nonsulfhydryl prodrug, Perindopril is metabolized to its active metabolite perindoprilat, providing sustained ACE inhibition with once-daily dosing. In quality control and regulatory contexts, Perindopril is supplied with comprehensive characterization data for analytical method development, method validation (AMV), and quality control applications. The unique octahydro-indole scaffold of Perindopril continues to serve as a template for medicinal chemistry research exploring novel ACE inhibitors and cardiovascular therapeutics.

 

Product Parameters

---

Parameter	Specification
Product Name	Perindopril
CAS Number	82834-16-0
Molecular Formula	C₁₉H₃₂N₂O₅
Molecular Weight	368.47 g/mol
Physical Form	Solid
Appearance	Off-white to light pink solid
Solubility	Soluble in water, chloroform, and methanol
Melting Point	100-101℃
Boiling Point	537.4±45.0℃
Storage Condition	2–8°C (refrigerator)

Bioactivity

---

Perindopril (S-9490) is a long-acting angiotensin-converting enzyme (ACE) inhibitor.

 

Application

---

1. Angiotensin-converting enzyme inhibitors are prodrug compounds that are metabolized into pedopril to become active. After oral administration, their ACE inhibition onset is slower compared to other ACE inhibitors. They are used for the treatment of hypertension.

 

2. For the treatment of hypertension, congestive heart failure, and other conditions.

 

3. Lubricant additive; Metal deactivator

 

Why Cosperpharm?

---

When your cardiovascular API manufacturing campaign or ANDA filing requires reliable ACE inhibitor intermediates and reference standards, Cosperpharm delivers Perindopril with the analytical rigor, documentation depth, and supply flexibility that pharmaceutical customers demand.

 

Therapeutic efficacy begins with purity. Perindopril is a complex chiral molecule with multiple stereocenters that must be precisely controlled for therapeutic efficacy. Any impurity in this API can compromise ACE inhibitory activity and clinical efficacy. Our analytical release protocol includes HPLC purity verification (≥98%), chiral purity verification, water content determination, and residual solvent analysis — because your final drug product's therapeutic profile depends on the quality of this API.

 

Documentation that supports regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch‑specific HPLC purity, chromatographic traceability, and residual solvent data — structured for direct insertion into your method validation package. DMF‑ready documentation, stability summaries, and custom quality agreements are available upon request.

 

Flexible supply across all development stages. Cosperpharm supplies Perindopril from 1g–50g quantities for analytical method development, to 100g–500g batches for process validation, to kilogram-scale quantities for commercial API manufacturing.

 

Technical support for the full synthetic cascade. Our process chemistry team can advise on synthetic route optimization, impurity profiling strategies, and analytical methods for detecting process-related impurities.

 

Global reach with transparent pricing. Cosperpharm ships worldwide with full customs documentation. Volume discounts apply at commercial scales.

 

Contact Us

---

Need Perindopril for your cardiovascular API manufacturing campaign, impurity profiling program, or analytical method development? Cosperpharm delivers with the quality, documentation, and supply reliability you require. Reach out to our team today — we respond within 2 business hours.